title: Pharmacotherapy versus T lymphocytes for CMV.
abstract: In this issue of Blood, Blyth et al report a phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received donorderived cytomegalovirus (CMV)-specific cytotoxic T cells (CTLs) and compare outcomes with a group of concomitant controls who were transplanted at the trial centers but who did not receive CTLs.
authors: Baylor College of Medicine, USA.
authors: Helen E
authors: HE
authors: Heslop
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology* / Q000517:prevention & control*; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D013601:T-Lymphocytes / Q000637:transplantation*; D014019:Tissue Donors
chemical_list: D000998:Antiviral Agents
references: Lancet. 2003 Oct 25;362(9393):1375-7
references: 14585640
references: Transfusion. 2011 Mar;51(3):591-9
references: 21133926
references: Blood. 2010 Nov 18;116(20):4360-7
references: 20625005
references: Nat Med. 2006 Oct;12(10):1160-6
references: 16998485
references: Clin Infect Dis. 2011 Jan 1;52(1):49-57
references: 21148519
references: Science. 1992 Jul 10;257(5067):238-41
references: 1352912
references: Blood. 2013 May 2;121(18):3745-58
references: 23435462
references: Mol Ther. 2012 Aug;20(8):1622-32
references: 22801446
references: Blood. 2010 Nov 25;116(22):4700-2
references: 20709906
references: Blood. 2005 Apr 1;105(7):2793-801
references: 15514011